Wednesday, Oct 20, 2021

Sept. 24, 2019 (NEW YORK, USA): The Executive Secretary of the Intergovernmental Authority on Development (IGAD), H.E. Amb (Eng) Mahboub Maalim, today signed a Memorandum of Understanding with Education Cannot Wait (ECW) for collaboration on the implementation of the Djibouti Declaration on Education for Refugees, Returnees and Host Communities in the IGAD Region. 

Read more ...

Sept. 16, 2019 (ADDIS ABABA, Ethiopia): The Inter-governmental Authority on Development (IGAD) in collaboration with the Government of the Federal Democratic Republic of Ethiopia today held a one-day Resource Mobilization Event and a panel discussion on the regional Cancer Initiative aimed at establishing an IGAD Regional Cancer Centre of Excellence (IGAD RCCE) in Addis Ababa.

Read more ...



June 19, 2019 (ENTEBBE ,Uganda) - During a 2-day meeting in Entebbe this week, members of the Intergovernmental Authority on Development (IGAD) Post-Marketing Surveillance Expert Working Group reviewed and validated the results from a first-of-its kind survey on the quality of oxytocin injection and amoxicillin dispersible tablet/suspension circulating in selected cross-border areas in the IGAD region.

The validated results were disseminated today to participating Member State national medicines regulatory authorities for appropriate corrective actions. Overall, the survey showed that 21% of oxytocin injection samples tested did not meet quality specifications. This means that women who may need this product during childbirth may be exposed to substandard medicines which may not be as effective as a quality-assured product. Encouragingly, the survey found that 100% of amoxicillin samples (both dispersible tablet and suspension) tested passed all quality tests.

In addition, 72% of oxytocin injection products, 30% of amoxicillin dispersible tablet products, and 26% of amoxicillin suspension products collected were not registered by the relevant national medicine regulatory authority. Medicine registration is an important way for national medicine regulatory authorities to control the quality of medicines.

The overall objective of the 2-day meeting was to review and validate the draft report on the quality of oxytocin injection and amoxicillin dispersible tablet/dry powder for oral suspension sampled from government, private and non-governmental health care facilities in selected cross-border areas in six IGAD Member States: Djibouti, Ethiopia, Kenya, Somalia, Sudan, and Uganda. The meeting also allowed Member States to validate a report of self-assessed capacity for pharmacovigilance in the region.

Specifically, the experts from Member States:

Validated post-marketing surveillance report and pharmacovigilance self-assessment report and propose recommendations for strengthening related activities in the IGAD region;

  1. Developed appropriate harmonized regulatory actions to be implemented by the member states;
  2. Reviewed challenges and lesson learned during the regional sampling exercise; and
  3. Provided recommendations for actions and solutions that will help assure the quality of medicines in the IGAD region.

Oxytocin is used to induce labour, and prevent and treat excessive bleeding after childbirth (also known as postpartum haemorrhage). Postpartum haemorrhage is an important cause of maternal death.

Amoxicillin is a widely used antibiotic drug for children and adults. The dispersible tablet and suspension forms are used to treat pneumonia and other bacterial infections in children.

Oxytocin and amoxicillin are both recommended treatments by the World Health Organization and are both widely available in low- and middle-income countries, including the IGAD region.

The sample collection exercise was conducted from December 2018 to February 2019 by experts from the national medicines regulatory authorities with guidance and coordination from the IGAD secretariat, the IGAD Expert Working Group Post-Marketing Surveillance and the Promoting the Quality of Medicines (PQM) program which is funded by the U.S. Agency for International Development and implemented by the U.S. Pharmacopeia.

Medicine regulatory systems strengthening for the marginalized and vulnerable cross-border mobile populations (CBMPs) in IGAD’s arid and semi-arid lands (ASAL) are often given limited attention and not regarded as a priority. CBMP communities include people living in cross-border areas, mobile pastoralists, refugees, seasonal labourers, economically active persons and undocumented migrants as well as internally displaced persons.

With the IGAD region becoming more integrated and barriers to trade and movement of people reduced, strengthening cross-border health systems, including those that support access to quality-assured medicines, need further attention by Member States and partners.


11-june-2019, (ENTEBBE, Uganda):Ensuring continuity of Tuberculosis (TB) treatment in the region is one of the critical concerns for The Intergovernmental Authority on Development (IGAD). IGAD in joint partnership with USAID and the USAID-funded Challenge TB (CTB) project continues to increase its focus on improving the health of Cross-Border and Mobile Populations (CBMP) and strengthening inter-country collaboration and referral systems for TB amongst its member governments. It is on this effort that IGAD convened a four-day experience sharing workshop for IGAD Member states National Tuberculosis (TB) Program on Cross-Border TB disease diagnosis, treatment, and continuity of care amongst the Member States.  

Conducted in the lakeside town of Entebbe, the workshop brought together TB Programme Managers, M&E experts, district/county TB focal persons and health care providers working in the cross-border health facilities in all IGAD member states. Also present were experts from the IGAD secretariat and Challenge TB who have been providing technical backstopping on cross-border TB.

The workshop followed a review of the country guidelines for TB management and an assessment on TB services in the IGAD cross-border areas in 2018. This particular assessment also reviewed the current inter-country TB patients referral system and informed the planning and implementation of cross-border TB activities. 

During the meeting:

  • Member states highlighted the changes already made or anticipated to the TB management guidelines in the region and progress towards regional standardization.
  • Member states outlined the steps so far taken to comply with the latest WHO guidelines on the management of TB.
  • A regional roadmap for intercountry referral system was developed, deliberated and agreed by the Member States.
  • Participants from the different border districts shared experiences and best practices on the management of cross-border TB.                    



12 April 2019, KAMPALA (Uganda): The Intergovernmental Authority on Development (IGAD) today closed a Validation Workshop for the Assessment of Cross Border Tuberculosis (TB) Services and Referral System in the IGAD Region in Kampala.

In 2018, IGAD Health and the USAID-funded Challenge TB (CTB) Project conducted assessments to gather information on the situation and services related to TB prevention and control at the IGAD countries border areas, and to understand the current inter-country TB presumptive and patient referral system.

The assessment collected data from 26 border areas Health facilities prioritized by IGAD for cross border activities and representing the IGAD member states of Ethiopia, Kenya, Somalia, South Sudan, Sudan and Uganda. Within each country, the teams conducted health  facility visits, interviews with stakeholders, and desk research to collect information.

This five-day workshop brought together the Heads of the National TB Programme (NTP), Experts on M&E and information system within the TB programme, and in-country national and district assessors who conducted the assessments.

During the workshop the Assessment Report of Health Services and Resources for Diagnosis and Management of Tuberculosis in Cross-border & Mobile Populations was validated, as well as the Report of IGAD Member States’ Inter-Country Referral System Assessment for Tuberculosis. Also, the participants provide input to the draft Minimum Package of TB Services for cross border and mobile populations and Inter-country TB referral/transfer notification system.

Speaking for the Director of the Health and Social Development Division, Fatuma Adan-Senior Regional program Coordinator encouraged the participants to “bear in mind the difficulties faced in the control of diseases among across national borders. “Please document and raise any challenges you learn in the  pilot to IGAD for appropriate regional policy interventions to help build resilient health systems in the region”, she concluded.

IGAD, through the joint partnership with USAID and the USAID-funded Challenge TB (CTB) project managed by the KNCV Nairobi regional office, continues to increase its focus on improving the health of cross border/mobile population (CBMP) and strengthening inter country referral systems for Tuberculosis amongst its member states..